Disease · MONDO_0015796
Comparisons in its trials29
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 29
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Rosuvastatin vs Placebo: serious adverse events | 34 of 379 | 32 of 366 | 745 | NCT00979121 | Trial comparisons |
| Albuterol Sulfate vs Placebo: serious adverse events | 1 of 152 | 1 of 130 | 282 | NCT00434993 | Trial comparisons |
| Part 2: TD-0903 - 3 mg vs Part 2: Matching Placebo: Part 2: Number of Participants Alive and Respiratory Failure-free on Day 28 | 92 of 106 | 85 of 104 | 210 | NCT04402866 | Trial comparisons |
| Group 1 - Ravulizumab + BSC vs Group 2 - BSC Alone: deaths from any cause | 55 of 135 | 25 of 66 | 201 | NCT04369469 | Trial comparisons |
| Group 1 - Ravulizumab + BSC vs Group 2 - BSC Alone: serious adverse events | 79 of 127 | 38 of 67 | 194 | NCT04369469 | Trial comparisons |
| Ascorbic Acid vs 5% Dextrose in Water: deaths from any cause | 25 of 84 | 38 of 83 | 167 | NCT02106975 | Trial comparisons |
| Ascorbic Acid vs 5% Dextrose in Water: serious adverse events | 0 of 84 | 0 of 83 | 167 | NCT02106975 | Trial comparisons |
| GM-CSF Group vs Placebo Group: serious adverse events | 31 of 64 | 34 of 66 | 130 | NCT00201409 | Trial comparisons |
| Enteral Fish Oil vs Enteral Saline: serious adverse events | 12 of 41 | 10 of 49 | 90 | NCT00351533 | Trial comparisons |
| Enteral Fish Oil vs Enteral Saline: Hospital Mortality | 9 of 41 | 10 of 48 | 89 | NCT00351533 | Trial comparisons |
| Enteral Fish Oil vs Enteral Saline: 60-day Mortality | 9 of 41 | 11 of 45 | 86 | NCT00351533 | Trial comparisons |
| Group A (Active) vs Group B (Control): Number of Participants With SUSAR's (Suspected Unexpected Serious Adverse Reaction) | 0 of 54 | 0 of 24 | 78 | NCT04382755 | Trial comparisons |
| Group A (Active) vs Group B (Control): All Cause Mortality for the Entire Study Population | 7 of 54 | 5 of 24 | 78 | NCT04382755 | Trial comparisons |
| Group A (Active) vs Group B (Control): Number of Participants With Lung Fibrosis on Chest CT Scan at Follow up | 0 of 54 | 0 of 24 | 78 | NCT04382755 | Trial comparisons |
| Group A (Active) vs Group B (Control): All-cause Mortality Rate (Including Group That Entered During Ventilation) | 5 of 54 | 5 of 24 | 78 | NCT04382755 | Trial comparisons |
| Group A (Active) vs Group B (Control): Number of Participants With Nosocomial Bacterial or Invasive Fungal Infection for 28 Days (Phone Call) After Enrollment in Trial | 12 of 54 | 4 of 24 | 78 | NCT04382755 | Trial comparisons |
| Group A (Active) vs Group B (Control): Number of Participants With Serious Adverse Events | 10 of 54 | 5 of 24 | 78 | NCT04382755 | Trial comparisons |
| Group A (Active) vs Group B (Control): deaths from any cause | 7 of 54 | 5 of 24 | 78 | NCT04382755 | Trial comparisons |
| Group A (Active) vs Group B (Control): Number of Participants With SAR's (Serious Adverse Reaction) | 0 of 54 | 0 of 24 | 78 | NCT04382755 | Trial comparisons |
| Group A (Active) vs Group B (Control): Number of Participants With Adverse Events | 39 of 54 | 17 of 24 | 78 | NCT04382755 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0015796/comparisons